You are here: Industry Insights > Everest

News List

Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Phase 3 Trial of Xerava(TM) for Community-Acquired Bacterial Pneumonia prnasia
August 05, 2021
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced today that the ...
Everest Medicines Receives Pediatric and Rare Severe Disease Priority Review Designation from Taiwan, China FDA for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer prnasia
July 29, 2021
Everest Medicines announced today that the Taiwan, China Food and Drug Administration (FDA) has granted Pediatric and Rare Severe Disease Priority Review Designation for sacituzumab govitecan-hziy (SG).
Everest Medicines Announces Strategic Collaboration with MediTrust Health Co., Ltd to Develop Novel Payment Solutions for Patients in China prnasia
July 21, 2021
Everest Medicines announced that it has entered into a strategic collaboration with MediTrust Health Co., Ltd, a leading innovative medical payment services provider and one of the largest pharmacy benefit management platforms in China.
Everest Medicines Announces Strategic Collaboration with Medbanks Health Technology to Develop Innovative Healthcare Service Solutions for Patients in China prnasia
July 14, 2021
Everest Medicines announced that it has entered into a strategic collaboration with Medbanks Health Technology, a pharmacy and healthcare services provider specializing in oncology.
Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia Territories prnasia
July 06, 2021
Everest Medicines announced that Spero Therapeutics, Inc., entered into a regional licensing agreement with Pfizer Inc. for SPR206.
Everest Medicines Announces China NMPA Has Accepted Biologics License Application for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer prnasia
May 17, 2021
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in Greater China and other parts of Asia, announced today that the China National Medical Products Administration (NMPA) ...
Everest Medicines Appoints Jennifer Yang as Chief Scientific Officer prnasia
April 15, 2021
Everest Medicines announced today the appointment of Dr. Jennifer Yang as chief scientific officer. Dr. Yang has two decades of leadership experience in drug discovery and development at global pharmaceutical companies.
Everest Medicines Announces China NMPA Approval of Clinical Trial Application to Evaluate Trodelvy® in a Phase 2 Basket Trial for a Variety of Cancers with High TROP-2 Expression prnasia
April 02, 2021
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced today that the ...
Everest Medicines Announces Acceptance of New Drug Application by China NMPA for Xerava(TM) for the Treatment of Complicated Intra-abdominal Infections prnasia
March 22, 2021
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced today that the ...
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2020 prnasia
March 22, 2021
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced its ...

Previous page 1 2 Next page